Adherence Challenges in Pediatric Patients with Tourette Syndrome Initiated on Dopamine D2 Receptor Modulators
Overview
This study highlights the increased incidence of adverse events and healthcare resource utilization in pediatric patients with Tourette syndrome treated with dopamine D2 receptor modulators. Notably, there was a significant decline in documented medication records over time, indicating potential adherence challenges.
Background
Tourette syndrome (TS) is a prevalent neurodevelopmental disorder affecting children and adolescents, often leading to significant impairments in quality of life. The use of dopamine D2 receptor antagonists/partial agonists (D2RAs) for TS treatment is common, yet these medications are associated with serious adverse effects that may impact treatment adherence. Understanding the real-world implications of D2RA treatment is crucial for optimizing care in this population.
Data Highlights
Cohort
Adverse Events Odds Ratio (95% CI)
Healthcare Resource Utilization Incidence Rate Ratio
The D2RA-exposed cohort showed a decline in documented medication records from 38.8% at Month 3 to 17.9% at Month 18.
Higher odds of mild adverse events (e.g., sleep disorder) were observed in the D2RA-exposed cohort.
Moderate adverse events (e.g., QT prolongation) had an odds ratio of 2.30 in the D2RA-exposed cohort.
Severe adverse events (e.g., tardive dyskinesia) had an odds ratio of 3.01 in the D2RA-exposed cohort.
Increased healthcare resource utilization was noted in the D2RA-exposed cohort compared to the nonexposed cohort.
Findings suggest potential residual confounding by indication and greater disease severity in the treated cohort.
Clinical Implications
Clinicians should be aware of the high incidence of adverse events associated with D2RAs in pediatric TS patients, which may affect treatment adherence. Continuous monitoring and patient education are essential to manage these risks and optimize treatment outcomes.
Conclusion
The study underscores the need for careful consideration of the risks associated with D2RA treatment in pediatric patients with Tourette syndrome, highlighting the importance of adherence strategies and ongoing patient support.
by Kinga K. Tomczak, Jason P. Swindle, Firas M. Dabbous, Donald L. Gilbert, George B. Karkanias, Sarah D. Atkinson, Frederick E. Munschauer, Faizan Mazhar, Charlotte A. Pettersson, Stephen P. Wanaski, Timothy M. Cunniff, David A. Isaacs
Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.
